Mr. Trump had been eager to celebrate his success at NATO and revel in the fact that he had conducted an attack that none of ...

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated increased ...

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new ...

IEEE Spatial Web chair George Percivall explains how the recently-approved IEEE P2874 Spatial Web Standard complements ...

Joby reports $127M Q1 2025 EBITDA loss but remains funded with $813M. Despite no commercial revenues, it trades at a ~$7B ...

Enrollment in company’s first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for ...

COMPETITIV - The new economy does not work with the mentalities and models of the old world. Leadership can no longer function in the absence of context. An op-ed by ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

Just as the United States should use its leverage with Israel to end its war with Iran, it should also use the credible ...